Business Wire

Aegerion’s Myalepta®▼ Approved in Europe : the First Treatment Indicated for Patients with Ultra-Rare Disease, Lipodystrophy

Jaa

Aegerion Pharmaceuticals today announced the granting of a marketing authorisation in Europe for Myalepta (metreleptin) by the European Commission. Myalepta is a treatment for the ultra-rare condition, lipodystrophy, and has been approved as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients. With this authorisation, Myalepta becomes the first and only licensed medication to treat the underlying leptin deficiency at the heart of this ultra-rare condition.

Professor Sir Stephen O’Rahilly, Professor of Clinical Biochemistry and Medicine at Addenbrooke’s Hospital, Cambridge, said, “Lipodystrophy is a rare condition which, due to its complex nature, requires highly specialised treatment. Patients with lipodystrophy have previously relied on lifestyle changes and medications, like insulin injections to manage the condition’s associated complications. Today’s milestone marks a significant change in the way lipodystrophy is treated. For the first time, we will be able to offer patients in Europe a treatment option that addresses one of the fundamental aspects of the condition itself.”

Rebecca Sanders, Founder and Chair of Lipodystrophy UK, said, “Lipodystrophy presents multiple ongoing challenges, both physical and psychological, to individuals living with the condition. Current available treatment options have been limited, address only some of the complications of the condition and are not specialised for lipodystrophy. Myalepta offers a long-term solution for patients and we are delighted that there is now a treatment available specifically to treat the complications of leptin deficiency in lipodystrophy which will give patients a much needed option to help improve both their disease and their quality of life.”

Lipodystrophy is an ultra-rare and incurable disease which impacts a person’s ability to store fat in their body, and can either be generalised (GL) or partial (PL).1 The condition is associated with a number of critical metabolic problems, such as severe diabetes, and can cause severe organ damage if uncontrolled.2 Globally, lipodystrophy affects approximately between 1 and 4 people per million.1

Paul Greenland, President EMEA at Aegerion Pharmaceuticals, said, “We are thrilled that patients with lipodystrophy in Europe will now have a specific treatment option. This also represents an exciting time for Aegerion as Myalepta becomes available in one of the largest global pharmaceutical markets. We will work collaboratively with patient organisations, health care professional and health services across Europe to enable access to as many patients as possible.”

#ENDS#

NOTES TO EDITORS

Data supporting approval of Myalepta

The safety and efficacy of Myalepta for the treatment of metabolic disorders, associated with lipodystrophy syndromes in pediatric and adult patients, were evaluated in a long-term, open-label, single-arm study conducted under the auspices of the National Institutes of Health (NIH) in the United States.

The observed primary efficacy results in patients with generalised lipodystrophy were:

  • A mean change from baseline to month 12 in HbA1c* of -2.2%; and
  • A mean percent change from baseline to month 12 in triglyceridesof -32.1%.3

In addition, 41% (16 of 39) of GL patients on insulin at baseline were insulin-free following treatment, 22% (7 of 32) of GL patients on oral anti-diabetic agents at baseline were able to discontinue, and 24% (8 of 34) of GL patients on lipid-lowering therapies at baseline were able to discontinue use of these therapies during Myalepta treatment.4

The observed primary efficacy results in the PL subgroup patients were:

  • A mean change from baseline to month 12 in HbA1c of -0.9%; and
  • A mean percent change from baseline to month 12 in triglycerides of -37.4%.3

The most frequently occurring adverse reactions from the clinical studies were hypoglycaemia (14%) and weight decreased (17%). Other common side effects (occurring inbetween 1 to 10% of patients) were decreased appetitite, headache, abdominal pain, nausea, alopecia, menorrhagia, fatigue, injection site bruising/erythema/reactions, neutralising antibody formation**.3

About lipodystrophy

Lipodystrophy is an ultra-rare condition that is characterised by the irreversible loss of adipose tissue.1 In patients with lipodystrophy, the lack of adipose tissue results in a loss of leptin production. Leptin is a naturally occurring hormone produced by subcutaneous fat and is an important regulator of energy homoeostasis, fat and glucose metabolism, reproductive capacity, and other diverse physiological functions.5

Lipodystrophy can be genetic or acquired after an immune condition and occurs in childhood or adolescence.6 Generalised lipodystrophy is a complete lack of fat affecting the whole body.7 Partial lipodystrophy is typically associated with a lack of fat in the arms, legs, head, and trunk regions while fat can accumulate in other areas of the body, including the neck, face and intra-abdominal regions affecting vital organs like the liver and heart.7

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a Novelion Therapeutics Inc. company: a biopharmaceutical company dedicated to developing and commercialising innovative new therapies for individuals living with rare and orphan diseases. Aegerion was acquired by Novelion Therapeutics Inc. in November 2016. The company’s European headquarters are situated in Windsor, UK.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Adverse events can be reported to Aegerion at

00800 23437466 or at medinfo.emea@aegerion.com

* HbA1c is a standard test used to measure an individual’s average blood sugar levels

Triglycerides are a type of fat in the blood

** Refer to the SmPC for a full list of adverse reactions (provided with this press release)

References

1 Chiquette, E., et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes, 2017. 10: p.375-383.

2 Pope, E., et al., Childhood acquired lipodystrophy: A retrospective study. Journal of the American Academy of Dermatology, 2006. 55(6): p. 947-950.

3 SmPC EMEA. Myalepta 11.3 mg powder for solution for injection. (provided with this document).

4 Brown, RJ., et al., Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine, 2018. 60(3): p.479-489.

5 Kelesidis, T., et al., Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications. Ann Intern Med, 2010. 152(2): p.93–100.

6 Brown, R.J., et al., The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab, 2016. 101(12): p. 4500-4511.

7 Fiorenza, C.G., et al., Lipodystrophy: Pathophysiology and Advances in Treatment. Nat Rev Endocrinol, 2011. 7(3): p. 137-150.

Contact information

Aegerion Pharmaceuticals
Charlotte Dawkins
Consultant, Patient Advocacy and Communications
07932 722950
charlotte.dawkins@aegerion.com
or
Harriet Reynolds
Senior Account Manager
Reynolds-MacKenzie
07384 438631
HarrietR@ReynoldsMackenzie.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Her Excellency Sheikha Hind Attends International Universities Arabic Debating Championship Closing Ceremony21.3.2019 18:03:00 EETTiedote

Her Excellency Sheikha Hind bint Hamad Al Thani, Vice Chairperson and CEO of Qatar Foundation (QF), attended the closing ceremony of the fifth edition of the International Universities Arabic Debating Championship (IUDC) organized by QatarDebate, a member of QF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005482/en/ Princess Sumaya University for Technology in Jordan takes First Place (Photo: AETOSWire) The championship – held under the patronage of Her Excellency Sheikha Hind bint Hamad Al Thani – took place at Qatar National Convention Centre from March 16-20, 2019, and included 107 teams from 51 Arab and non-Arab countries. During the ceremony, Her Excellency Sheikha Hind presented the winners with their awards. The debate team from Princess Sumaya University for Technology in Jordan took first place in this year’s edition of IUDC. The boys’ team from Qatar University was awarded second place, while the team from

Taulia Enhances Platform with New Artificial Intelligence Capabilities in a World First for Working Capital Solutions21.3.2019 18:00:00 EETTiedote

Harnessing the latest developments in AI technology, Taulia’s upgraded platform supports simplified, informed decision-making and strengthens the buyer-supplier relationships. Taulia has upgraded its platform with a set of new world-class AI capabilities. Rate of suppliers taking advantage of early payment offers increases three fold. The enhanced platform supports companies in making better informed decisions about their working capital and cash. Working capital solutions provider, Taulia, has rolled out a new version of its buyer platform, bringing enhanced artificial intelligence (AI) capabilities to its programs. Companies now have the power of AI at their fingertips with the next-level enhancement of Taulia’s platform. The platform taps into aggregated data on supplier behavior, such as the historic timing of payments and the annual percentage rate (APR) accepted by suppliers when taking early payment, plus other factors including seasonality. By overlaying this with external data

Life-Sciences and Healthcare Communications Leaders John “Zeke” Czekanski and Scott Roberts Join Citrus Global Healthcare Communications Group as Managing Partners21.3.2019 17:21:00 EETTiedote

Industry leaders John “Zeke” Czekanski and Scott Roberts have joined Citrus Global Healthcare Communications Group as Managing Partners. Zeke will oversee Citrus Scientific while Scott brings his extensive global market access and value experience in guiding Citrus Access. Together they will actively co-manage Citrus Strategy, providing insights enabling clients to innovate with confidence, broaden opportunities, and drive meaningful human-health outcomes forward. “I’m thrilled to be part of the Citrus Group working in partnership with our clients, the medical community, payers, government agencies, and global healthcare stakeholders. We look forward to delivering meaningful scientific insights and market-access solutions,” commented Zeke. Scott added, “There is a critical need in our industry, especially with highly innovative small to mid-size life-science companies, for a transformational agency applying data and analytics along with a holistic approach to the communications continu

Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development21.3.2019 16:44:00 EETTiedote

Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service to assist customers in selecting and developing the best lead candidate to take forward for manufacture. The new Developability Service reduces the time, risk and cost required to take multiple lead candidates through cell line development and manufacturing. Biologics have potential liabilities for safety, functionality, stability and scalability and when these issues are identified early alternate leads can be selected, liabilities engineered out or measures can be taken to mitigate risk. The Developability Service also enables the selection of drug candidates most aligned with the target product profile by evaluating a range of functionality and specificity readouts. The s

XPRIZE Identifies 10 Future Breakthroughs Required to Protect Our Forests21.3.2019 16:27:00 EETTiedote

Today, on the United Nations’ International Day of Forests, XPRIZE is releasing the Future of Forests Impact Roadmap, created in partnership with Kimberly-Clark Corporation. The digital report and its interactive website, based on future foresight techniques, illustrate the breakthroughs required for a healthier forest ecosystem, which might be the basis of future XPRIZE competitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005409/en/ Across the world, forests provide food security and shelter, protect biodiversity and house indigenous populations. While forests cover more than 30 percent of the Earth’s surface, more than 32 million acres of forests are lost due to human activity every year, with research showing that continued mass deforestation and degradation is accelerating climate change. XPRIZE designs and operates global competitions to incentivize the development of technological breakthroughs that accel

Mark Thorne Joins BCW as Global Chief Financial Officer and Chief Operating Officer21.3.2019 16:17:00 EETTiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, announced today that Mark Thorne has been appointed Global Chief Financial Officer and Chief Operating Officer, effective immediately. Thorne will be a strategic partner to BCW Global CEO Donna Imperato in transforming the agency’s financial model to better reflect its wide range of services and offerings. He is based in New York and replaces Pat Przybyski, formerly Global Chief Financial Officer. “Mark is well known for his strong business acumen, deep operational experience and high-level strategic thinking,” said Imperato. “I have known Mark for many years and am thrilled to now call him my partner. He is the right leader to help BCW execute our strategies and grow exponentially.” Thorne spent the past 20 plus years with Hill+Knowlton Strategies in a range of leadership roles, most recently serving as Global Chief Financial Officer and Global Chief Operating Officer. Prior to that, Thorne was Executive Vice President

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme